Inogen, Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2015. Unless otherwise noted, financial amounts below are in millions of U.S. dollars; the filing reports financial statements in thousands. The filing was signed May 12, 2015.
Business context
Inogen develops, manufactures and sells or rents portable oxygen concentrators and related products. It operates one business segment and uses both direct-to-consumer sales and business-to-business distribution. Revenue came from U.S. and international product sales and U.S. rentals; international revenue was 25% of total revenue, versus 19% a year earlier. The company reported approximately 30,000 rental patients, up from approximately 23,000 at March 31, 2014.
Financial performance and liquidity
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Total revenue | $33.752 | $23.633 |
| Sales revenue | $23.049 | $14.857 |
| Rental revenue | $10.703 | $8.776 |
| Gross profit / gross margin | $16.023 / 47.5% | $11.938 / 50.5% |
| Income from operations | $2.518 | $1.549 |
| Net income | $1.572 | $0.888 |
| Diluted EPS | $0.08 | $(0.01) attributable to common stockholders |
| Operating cash flow | $6.061 | $(1.330) |
| Investing cash flow | $(4.040) | $(3.228) |
| Adjusted EBITDA (non-GAAP) | $6.375 | $4.345 |
Revenue increased 42.8% year over year: sales rose 55.1% and rentals 22.0%. Management attributed sales growth to higher system volumes, stronger direct-to-consumer activity and international business-to-business demand. Approximately 11,000 systems were sold, compared with 6,300 in Q1 2014. Sales gross margin declined to 45.4% from 49.2%, primarily because business-to-business sales made up a larger share of sales; rental gross margin was 52.0%, versus 52.7%. Higher sales and marketing, general and administrative, and research and development costs partially offset gross-profit growth.
Cash and cash equivalents were $61.102 at March 31, 2015, compared with $56.836 at year-end 2014. Operating cash flow improved, though receivables growth and slower rental-receivable collections used cash. The company invested $3.477 in rental equipment during the quarter. Long-term debt was approximately $0.540, consisting of patent-related debt; there were no borrowings under the $15.0 revolving credit facility, and the company reported covenant compliance. Management believed cash, available credit and expected operating cash flows would cover projected needs for at least 12 months.
Changes, outlook and management commentary
- Overall gross margin fell three percentage points year over year despite higher revenue and gross profit. Rental returns were also higher and weighed on rental revenue and margin.
- General and administrative expense rose 41.2%. About $0.9 of Q1 legal and audit/tax costs related primarily to an audit committee investigation. Management expected a further $0.1–$0.6 of investigation expense in Q2 and anticipated additional costs related to securities litigation.
- Management expected to launch an upgraded Inogen One G3 by year-end 2015 and the smaller, lighter Inogen One G4 in the first half of 2016. These are stated plans, not a guarantee of launch or commercial results.
- Management estimated that CMS reimbursement changes applying regional competitive-bidding prices to certain previously unbid areas could reduce 2016 revenue by approximately 3–4%. This is an estimate, not full-year revenue guidance. Medicare accounted for 82% of rental revenue and 26% of total revenue in Q1 2015.
- Management cited reimbursement-rate pressure, capped Medicare rentals, payer audits and documentation requirements, competition, and dependence on a limited number of component suppliers as important risks. Approximately 15.3% of rental patients were in the capped period at quarter-end.
Controls, contingencies and unusual items
- The company disclosed a material weakness in controls over review of sales-order documentation supporting direct-to-consumer sales and rentals. Management said disclosure controls were not effective as of March 31, 2015; remediation was underway, but timing and success were uncertain. Management nevertheless stated the financial statements fairly presented the periods shown.
- Two securities class-action complaints alleged that company disclosures and financial statements concerning internal controls were misleading. One plaintiff voluntarily dismissed the second-filed action without prejudice after quarter-end; the company could not estimate the likelihood or range of loss in the remaining action.
- A long-running patent infringement lawsuit against Inova Labs remained stayed pending patent reexamination. The company also disclosed routine legal proceedings and healthcare-regulatory compliance risks.
- The company filed its 2014 Form 10-K late. Nasdaq notified it of noncompliance, then confirmed compliance after the 10-K was filed on April 27, 2015. The late filing made the company ineligible to raise capital on Form S-3 for 12 calendar months from the late filing date; it would need to use Form S-1 instead.
- Q1 2014 common-stockholder EPS included a $0.987 deemed preferred-stock dividend, contributing to the reported common-stockholder loss despite positive net income. In Q1 2015, basic and diluted EPS were both $0.08.
Important facts for investors to verify
- Progress and independent validation of remediation for the revenue-documentation material weakness, and whether later filings remain timely and reliable.
- Medicare and other payer reimbursement changes, capped-patient trends, collections, claim reviews and rental-return rates.
- Whether product launches occur on schedule and whether increased sales volumes translate into improved margins and cash generation.
- Final costs and outcomes of the audit committee investigation and securities litigation; the filing provides no estimable loss range for the remaining class action.
- Cash conversion and rental-fleet investment needs, including the pace of receivables growth and continued covenant compliance.